Review of real-world dosing strategies, treatment patterns, and clinical outcomes for pharmacologic management of ACTH-dependent Cushing's syndrome.
Key Takeaways
- Osilodrostat achieved therapeutic biochemical control in 92% of patients within 14 days
- Morning cortisol normalized in 92% of patients and urinary cortisol in 75%
- Eighteen of twenty patients with diabetes reduced antidiabetic medications or insulin